Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ramucirumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ALX Oncology Reports Q2 2024 Results And Corporate Update
    ALX Oncology Reports Q2 2024 Results And Corporate Update

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2927332/0/en/ALX-Oncology-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Elevation Oncology Reports Q2 2024 Results And Achievements
    Elevation Oncology Reports Q2 2024 Results And Achievements

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/elevation-oncology-reports-second-quarter-2024-financial-results-and-highlights-recent-business-achievements-302215419.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    The China NMPA Approved CYRAMZA for the Treatment of Hepatocellular Carcinoma
    The China NMPA Approved CYRAMZA for the Treatment of Hepatocellular Carcinoma

    09 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/the-china-nmpa-approved-cyramza-ramucirumab-for-the-treatment-in-patients-with-hepatocellular-carcinoma-301644363.html

    PRNEWSWIRE
    09 Oct 2022
    Share Share
    Eli Lilly's Biologic Cyramza (Ramucirumab) Receives Approval in the U.S.
    Eli Lilly's Biologic Cyramza (Ramucirumab) Receives Approval in the U.S.

    22 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477

    FDA
    22 Mar 2022
    Share Share
    Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer
    Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer

    14 Jan 2022

    // TRIALSITENEWS

    https://trialsitenews.com/pieris-pharmaceuticals-announces-first-patient-dosed-phase-2-gastric-cancer-trial-evaluating-4-1bb-her2-bispecific-cinrebafusp-alfa/

    TRIALSITENEWS
    14 Jan 2022
    Share Share
    Edesa finds a signal in severely ill Covid-19 patients
    Edesa finds a signal in severely ill Covid-19 patients

    21 Sep 2021

    // Elizabeth Cairns EVALUATE

    https://www.evaluate.com/vantage/articles/news/trial-results/edesa-finds-signal-severely-ill-covid-19-patients

    Elizabeth Cairns EVALUATE
    21 Sep 2021
    Share Share